Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Available Treatment Options for Patients With EGFR Mutant NSCLC

January 3rd 2022

Tony SK Mok, MD, and Solange Peters, MD, PhD, relay the available treatment options for EGFR mutant NSCLC—both early and advanced stages.

ADAURA and Selecting Adjuvant Therapy in EGFR Mutant Early-Stage NSCLC

January 3rd 2022

Dr Mok finishes our discussion on the ADAURA trial, and Dr Peters delves into selecting the right adjuvant therapy for a patient with early-stage EGFR mutant NSCLC.

Biomarkers Light the Way for Personalized Treatment in NSCLC

December 30th 2021

Jyoti D. Patel, MD, discusses biomarker testing, interpreting molecular result reports, and the growing armamentarium for patients with oncogene-driven lung cancer.

Novel Combination Looks to Capitalize on Synergy of B7-H3/PD-1 Blockade

December 30th 2021

The investigational monoclonal antibody enoblituzumab has demonstrated activity in preclinical studies and in combination with pembrolizumab in phase 1/2 studies in patients with checkpoint inhibitor–naïve head and neck squamous cell carcinoma and non–small cell lung cancer.

Shifting Regulatory Approval Pathway Is a Top Takeaway of 2021 in Lung Cancer

December 29th 2021

The shift away from accepting only positive overall survival (OS) data from phase 3 trials as the pathway toward regulatory approval has been the biggest takeaway from 2021 in lung cancer.

LEMS Case Review

December 28th 2021

Drs. David Gerber and Steven Vernino review the case of a 64-year-old man with Lambert-Eaton myasthenic syndrome.

LEMS Diagnosis: Patient Presentation and Testing

December 28th 2021

Two experts debate the preferred testing options for Lambert-Eaton myasthenic syndrome presenting with small cell lung cancer.

Dr. Johnson on New Drug Approvals for EGFR Exon 20 Insertion Mutation+ NSCLC

December 23rd 2021

Melissa L. Johnson, MD, discusses new drug approvals for EGFR exon 20 insertion mutation–positive non–small cell lung cancer.

Dr. Gold on Current Unmet Needs in Squamous Cell Carcinoma of the Lung

December 23rd 2021

Kathryn A. Gold, MD, medical oncologist, professor of medicine, UC San Diego Health, discusses current unmet needs in squamous cell carcinoma of the lung.

FDA Grants Breakthrough Therapy Designation to Patritumab Deruxtecan for EGFR+ NSCLC

December 23rd 2021

The FDA has granted a breakthrough therapy designation to patritumab deruxtecan for the treatment of patients with metastatic or locally advanced EGFR-mutated non–small cell lung cancer with disease progression on or after treatment with a third-generation TKI and platinum-based therapies.

Dr. Gold on Leveraging Sotorasib in KRAS G12C–Mutated NSCLC

December 22nd 2021

Kathryn Gold, MD, discusses best practices with the use of sotorasib in patients with KRAS G12C–mutated non–small cell lung cancer.

Second-Line Treatment of SCLC

December 22nd 2021

Vamsidhar Velcheti, MD, leads the discussion on the current standard of care and approaching the treatment of second-line SCLC.

Updated Results of the CASPIAN Trial in SCLC From ESMO 2021

December 22nd 2021

John V. Heymach, MD, PhD, reviews updated results from the phase III CASPIAN trial for patients with extensive-stage SCLC (small cell lung cancer) as presented at ESMO 2021.

Immunotherapies in the Treatment of Extensive-Stage SCLC

December 22nd 2021

Sandip P. Patel, MD, reviews results and clinical implications from the CASPIAN study, and Heather Wakelee, MD, shares insight on approaching the optimal immunotherapy option for patients with extensive-stage SCLC.

Considerations for Biomarker Testing in NSCLC: Gene Panel Size and Reimbursement

December 22nd 2021

Shared insight on how comprehensive biomarker testing should be in non–small cell lung cancer, as well as what may or may not be reimbursed.

Regional Recommendations and Approaches to Biomarker Testing in NSCLC

December 22nd 2021

Expert oncologists from key Asian countries share guidelines for biomarker testing in their countries and how biomarker testing is being used for non–small cell lung cancer in their region.

Testing for LEMS

December 21st 2021

A neurologist explains how to test for and diagnose Lambert-Eaton myasthenic syndrome.

Defining LEMS

December 21st 2021

David Gerber, MD, and Steven Vernino, MD, PhD, provide an overview of Lambert-Eaton myasthenic syndrome and its association with cancers.

FDA Approvals Signify a Successful 2021 in Lung Cancer, But Resistance to Available Therapies Remains a Top Concern

December 21st 2021

The FDA approvals of several targeted therapies, such as sotorasib, amivantamab-vmjw, and mobocertinib, as well as immunotherapeutic strategies, such as adjuvant atezolizumab, represent significant advances made in 2021 for the treatment of patients with non–small cell lung cancer.

Adjuvant Therapy for EGFR Mutant Early-Stage NSCLC: ADAURA

December 20th 2021

Drs Peters and Mok discuss adjuvant therapy for patients with early-stage EGFR mutant NSCLC and the impact of the ADAURA clinical trial on how we treat this disease.